BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
BioAtla, Inc. (BCAB)
Company Research
Source: Yahoo! Finance
General and Administrative Expenses: $5.9 million for Q3 2024, down from $6.6 million in Q3 2023. Net Loss: $10.6 million for Q3 2024, compared to $33.3 million in Q3 2023. Net Cash Used in Operating Activities: $55.2 million for the nine months ended September 30, 2024, compared to $74.1 million for the same period in 2023. Cash and Cash Equivalents: $56.5 million as of September 30, 2024, compared to $111.5 million as of December 31, 2023. Collaboration Revenue: $11 million recognized in Q3 2024 from a license agreement with Context Therapeutics. Warning! GuruFocus has detected 1 Warning Sign with BCAB. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript BioAtla Inc ( NASDAQ:BCAB ) reported promising clinical trial results for its drug candidate, Tab war 2 80 C Zy A THEIN, showing a total of 11 responses out of 29 evaluable patients with refractory head and neck cancer. The drug candid
Show less
Read more
Impact Snapshot
Event Time:
BCAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAB alerts
High impacting BioAtla, Inc. news events
Weekly update
A roundup of the hottest topics
BCAB
News
- BioAtla, Inc. (NASDAQ: BCAB) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.MarketBeat
- BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress [Yahoo! Finance]Yahoo! Finance
- BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent ProgressGlobeNewswire
- BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024GlobeNewswire
- BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy [Seeking Alpha]Seeking Alpha
BCAB
Earnings
- 11/7/24 - Beat
BCAB
Sec Filings
- 11/14/24 - Form SC
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- BCAB's page on the SEC website